Evaluating AT101 for patients with relapsed B-cell Non-Hodgkin's Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety, tolerability, and efficacy of AT101, an anti-CD19 chimeric antigen receptor T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study will determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) for this patient population. Participants will be monitored for their response to the treatment and any adverse effects experienced during the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* B cell non-Hodgkin lymphoma based on WHO classification 2017
* incompatible with existing standard therapies or have had disease progression, and whose standard therapies do not currently have available standard therapies due to reasons such as intolerance/inadequacies or rejection
* The Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening
* Those with a minimum life expectancy of 12 weeks or more
* In women with childbearing, clinical response tests (serum- or ure-hCG) were negatively identified during this trial
* Those who have agreed in writing to participate voluntarily in this trial

Exclusion Criteria:

* Those who have previously had a history of treating homologic autologous hemoblastitis (allogeneic HSCT)
* At101/adcidmilisers, anticancer chemotherapy/adcidms for lymphodeletion or those who are hypersensitive to tocilizumab
* Those who cannot take autologous blood
* Those who have received chemotherapy or radiotherapy, excluding lymphodeletion, within two weeks prior to IP administration
* Persons who have not been recovered (CTCAE grade ≤1 or baseline) due to previous treatment
* Those who have identified a condition that, at the test's discretion, may affect safety and validation during the trial period.
* Those who have identified the following forces at the time of screening:

  1. Those who have been clinically aware of heart disease within 6 months prior to screening
  2. Those identified as thromboembolic disease, pulmonary embolism or bleeding bleeding diatheses within 6 months prior to screening
  3. Those who have identified a history of malignant tumors other than B-cell non-Hodgkin's lymphoma within five years prior to screening
  4. Those who have undergone major surgery within 4 weeks prior to screening
  5. Those who have undergone non-critical surgery within two weeks prior to screening
* Childbearing women or men who do not have the will to use effective contraception for a longer period of time, either 12 months after clinical trial period and AT101 administration or when AT101 in the body is not identified
* Those who have been administered or applied to other IP/ID within 4 weeks of screening
* Those who are addicted to alcohol and/or medication
* Those who are unfit or unable to participate in this trial when judged by PI

Where it's running

• Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Deok-hyun Yoon — Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea
• Study coordinator: Young ha Lee
• Email: yhlee@abclon.com
• Phone: 82-2-2109-1283

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GI001 CAR-T for relapsed or refractory B-cell NHL and B-ALL

  This treatment study tests GI001, an in vivo CAR-T therapy, to see if it is safe and helpful for adults with relapsed or refractory B-cell NHL or B-ALL.

  Recruiting Early Phase 1 Hematology department of the 920th hospital · Yunnan, Kunming · NCT07862010

• ARC-02 with Rituximab for B-cell non-Hodgkin lymphomas

  This study tests ARC-02, together with Rituximab, to see if the treatment is safe and shows early signs of activity in people with B-cell non-Hodgkin lymphomas who have already tried multiple therapies.

  Recruiting at 3 sites Phase 1 Taiho Oncology, Inc. · Los Angeles, California and 27 other locations · NCT07691606

• SHR-3079 in B-cell non-Hodgkin lymphoma

  This small early study tests SHR-3079 in adults with B-cell non-Hodgkin lymphoma to see if it is safe and tolerable and to find a workable dose for future testing.

  Recruiting at 2 sites Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07661537

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• First-in-human test of DS3790a for hematological malignancies

  This first-in-human trial will test DS3790a alone and with other drugs to see if it's safe, how it behaves in the body, and whether it helps adults with hematological malignancies.

  Recruiting at 8 sites Phase 1/2 Daiichi Sankyo · New York, New York and 7 other locations · NCT07220616

• AZD4512 alone or with other medicines for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial will try AZD4512 by itself or with other cancer drugs to see if it helps adults whose B‑cell non‑Hodgkin lymphoma has relapsed or not responded after prior treatments.

  Recruiting at 16 sites Phase 1/2 AstraZeneca · Irvine, California and 22 other locations · NCT07123454

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.